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Abstract
Background: G protein coupled receptors (GPCRs) are one of the most widely studied gene superfamilies.
Thousands of GPCR research studies have utilized heterologous expression systems such as human embryonic
kidney cells (HEK293). Though often treated as ‘blank slates’, these cell lines nevertheless endogenously express
GPCRs and related signaling proteins. The outcome of a given GPCR study can be profoundly influenced by this
largely unknown complement of receptors and/or signaling proteins. Little easily accessible information exists that
describes the expression profiles of the GPCRs in cell lines. What is accessible is often limited in scope - of the
hundreds of GPCRs and related proteins, one is unlikely to find information on expression of more than a dozen
proteins in a given cell line. Microarray technology has allowed rapid analysis of mRNA levels of thousands of
candidate genes, but though often publicly available, the results can be difficult to efficiently access or even to
interpret.
Results: To bridge this gap, we have used microarrays to measure the mRNA levels of a comprehensive profile of
non-chemosensory GPCRs and over a hundred GPCR signaling related gene products in four cell lines frequently
used for GPCR research: HEK293, AtT20, BV2, and N18.
Conclusions: This study provides researchers an easily accessible mRNA profile of the endogenous signaling
repertoire that these four cell lines possess. This will assist in choosing the most appropriate cell line for studying
GPCRs and related signaling proteins. It also provides a better understanding of the potential interactions between
GPCRs and those signaling proteins.
Background
The G protein-coupled receptor (GPCR) gene superfam-
ily consists of hundreds of members that are widely
expressed in all tissues and serve as receptors for a
diverse complement of ligands. Approximately 100 of
these receptors are considered orphan GPCRs, in that
no endogenous ligand has been confirmed for them [1].
Characterized by having seven transmembrane alpha-
helical domains [2], GPCRs mediate a wide spectrum of
cellular processes ranging from cell growth to neuro-
transmission [1-3]. A number of classification systems
for GPCRs have been developed as bioinformatic tools
[3-5]. One of the most commonly used GPCR
classification systems, the one set forth by Kolakowski
and developed by Vriend [4,6,7], groups GPCRs into six
classes based on structural similarities to prototypical
receptors. Class A GPCRs are the most abundant (>80%
of all GPCRs), defined by a high sequence homology to
rhodopsin, and include the chemosensory receptors.
C l a s sBG P C R sa r ea l s ok n o w na ss e c r e t i n - l i k er e c e p -
tors. Class C GPCRs are the metabotropic glutamate-
like receptors. Class F/S receptors consist of frizzled/
smoothened receptors, though there is debate about
their ability to couple to G proteins [2]. Class D/Fungal
pheromone and Class E/cAMP receptors are absent in
mammals.
On activation via ligand binding, GPCRs couple to het-
erotrimeric G proteins composed of three subunits: Ga,
b and g. G protein a subunits are classified as members
of one of four groups: Gi/o,G s,G q,a n dG 12/13 [8].
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(e.g. adenylyl cyclases) through which cellular activity is
modulated. The Gb/g G protein subunits are capable of
acting at their own specific targets, such as modulating
ion channel activity [9-11]. The available complement of
heterotrimeric G proteins will therefore affect its
response profile.
A regulatory system controls the timing and duration
of GPCR signaling. GPCR kinases (GRKs) phosphorylate
agonist-occupied receptors, typically leading to receptor
desensitization. Beta-arrestins are scaffolding proteins
that are recruited to activated GPCRs and prevent G
protein association with the receptor. They also serve to
spatially segregate GPCR signaling to molecules such as
mitogen-activated protein kinases [12,13]. The Regula-
tors of G protein signaling (RGS) proteins, which
enhance the GTPase activity of Ga subunits, is another
large family of proteins important in fine-tuning GPCR
signaling [14,15].
Due to their central roles in many cellular functions,
GPCRs are important therapeutic targets. Different
reports estimate that between 30 and 50% of all pre-
scription drugs target GPCRs. Interestingly, these drugs
only target ~10% of the non-chemosensory receptors,
leaving hundreds of GPCRs as potential drug targets
[2,9,16].
Identifying ligands, studying receptor protein interac-
tions, and measuring cellular effects of receptor activation
is often achieved by heterologous expression of GPCRs in
cell lines such as HEK293 and AtT20 [17,18]. They also
serve as models of cell types from which they are drawn
(e.g. BV2 for microglia and N18 for neurons) [19-21].
However these cell lines have remained something of a
black box; researchers make use of them without full
knowledge of the complement of GPCRs and related pro-
teins. The presence of an unknown protein in these cell
lines may confound an otherwise sound series of experi-
ments and differential expression of GPCRs and their
regulatory proteins may explain differences in reported
results across cell lines [13,17,22-25]. It is also clear that
GPCRs can form oligomers with other GPCRs. These oli-
gomers may confer different signaling properties to a
transfected GPCR of interest, and can add layers of varia-
bility and complexity.
Efforts to define expression of GPCRs, on a receptor-
by-receptor basis, using polymerase chain reaction
(PCR)-based methods have only scratched the surface.
Even for the widely used HEK293 cells, the expression
of fewer than thirty GPCRs has been described [17,26].
Recently developed high-throughput methods have
made possible the simultaneous assay of mRNA levels
for thousands of genes. Microarray analyses have
matured sufficiently in terms of accessibility and cost to
make their application to this question tractable. We are
not the first to make use of microarray technology to
examine mRNA expression levels in HEK293 cells [26],
however, most studies that have used microarray ana-
lyses on these cell lines have examined specific gene
products of interest and reported data only for those
gene products [20,26-28]. Their full data sets are avail-
able through NCBI, but are difficult for the non-specia-
list user to access and collate.
As a consequence, we sought to identify and make
accessible the full complement of endogenously
expressed non-chemosensory GPCRs of four cell lines
used in GPCR research: the HEK293, AtT20, BV2 and
N18 lines. Using microarray analysis we measured the
mRNA levels from each of these four cell lines specifi-
cally identifying the expression levels of GPCRs and
over a hundred of GPCR-related gene products and
report them here.
Results
We first examined HEK293 cells, a cell line that was
made by transforming human embryonic kidney cells
with adenovirus type 5 DNA. Developed in 1977,
HEK293 cells may be the single most widely used cell
line for heterologous expression (both transient and
stable expression) of GPCRs and other proteins of inter-
est [17]. Figures 1,2,3,4,5 and 6 show the mRNA levels
of GPCR and GPCR-related gene products found in
HEK293 cells. Of Class A GPCRs, shown in figures 1
and 2, HEK293 cells express mRNA for several different
types of receptors within specific families of receptors:
multiple types of adenosine, lysophospholipid, puriner-
gic, prostanoid, and protease-activated receptors, among
others. In results relevant to the study of orphan GPCRs
(figure 3), HEK293 cells contain high message levels of
GPR37, 2 types of orphan-LGR (glycoprotein hormone)
receptors–LGR4 and LGR5, GPR39–and very high levels
of the melatonin-related receptor GPR50. HEK293 cells
may therefore be suitable tools for deorphanization of
these receptors. Interestingly, HEK293 cells contain rela-
tively little mRNA for Class B GPCRs with known
ligands (figure 4A), but quite high levels of many orphan
Class B GPCRs. The same is true for Class C GPCRs as
seen in figure 4B though they do appear to contain high
levels of GABABR1 receptor message, though lacking
mRNA for GABABR2, necessary to form a fully func-
tional GABA-B receptor. Finally, for GPCRs, HEK293
cells contain a number of types of frizzled receptors as
well as smoothened receptor (figure 4C). Figures 5 and
6 show the mRNA levels of various types of GPCR sig-
naling-related gene products such as the G proteins and
a number of their targets and downstream effectors as
well as proteins that regulate GPCR signaling, the GRK,
beta-arrestin (ARRB) and RGS proteins. Interestingly
HEK293 cells express mRNA for numerous isoforms of
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Page 2 of 14Figure 1 mRNA expression levels of Class A GPCRs. Microarray analysis of mRNA levels of Class A GPCRs with known ligands for HEK293,
AtT20, BV2 and N18 cell lines. The gray line indicates the threshold of statistical significance and the dark bars are proteins for which statistically
significant levels of mRNA were detected. White bars indicate levels of mRNA for proteins that were present, but did not reach statistical
significance. Abbreviation: 5-HT = 5-hydroxytryptamine; GNRH = Gonadotrophin-releasing hormone.
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Page 3 of 14Figure 2 mRNA expression levels of Class A GPCRs. Microarray analysis of mRNA levels of Class A GPCRs with known ligands for HEK293,
AtT20, BV2 and N18 cell lines. The gray line indicates the threshold of statistical significance and the dark bars are proteins for which statistically
significant levels of mRNA were detected. White bars indicate levels of mRNA for proteins that were present, but did not reach statistical
significance. Abbreviation: MCH = Melanin-concentrating hormone; TRH = Thyrotropin-releasing hormone.
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Page 4 of 14Figure 3 mRNA expression levels of Class A Orphan GPCRs. Microarray analysis of mRNA levels of Class A GPCRs with unknown ligands for
HEK293, AtT20, BV2 and N18 cell lines. The gray line indicates the threshold of statistical significance and the dark bars are proteins for which
statistically significant levels of mRNA were detected. White bars indicate levels of mRNA for proteins that were present, but did not reach
statistical significance. Abbreviation: ND = not determined.
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Page 5 of 14Figure 4 mRNA expression levels of Class B, C, and F/S GPCRs. Microarray analysis of mRNA levels of GPCRs with known ligands for HEK293,
AtT20, BV2 and N18 cell lines. A: Class B GPCRs. B: Class C GPCRs. C: Class F/S GPCRs. The gray lines indicate the threshold of statistical
significance and the dark bars are proteins for which statistically significant levels of mRNA were detected. White bars indicate levels of mRNA
for proteins that were present, but did not reach statistical significance. Abbreviations: BAI = Brain-specific angiogenesis inhibitor; CELSR =
Cadherin EGF LAG seven-pass G-type receptor; CRF = Corticotropin-releasing factor; ND = Not determined; PACAP = pituitary adenylyl cyclase-
activating polypeptide; VIP = Vasoactive intestinal peptide.
Atwood et al. BMC Genomics 2011, 12:14
http://www.biomedcentral.com/1471-2164/12/14
Page 6 of 14adenylyl cyclase and protein kinases A and C (PRKA,
PRKC) and phospholipase C (PLC), while having a lim-
ited diversity of phospholipase A (PLA) and RGS pro-
teins. HEK293 cells also appear to have an almost full
complement of G protein isoforms for each subunit,
making these cells an attractive environment to express
any number of GPCRs to study downstream G protein-
mediated signaling.
Next we analyzed the AtT20 cell line, a neuroendo-
crine line derived from a mouse pituitary tumor that
has neuron-like properties [29]. This cell line is often
used as a model neuroendocrine cell line and has been a
useful cell line to study of ion channel modulation by
GPCRs [18,30,31]. Unlike HEK293 cells, there has been
relatively little work performed to identify the GPCRs
and related signaling molecules present in AtT20 cells.
Our current results highlight that AtT20 cells express a
diverse range of GPCR mRNAs. Figures 1 and 2 show
that they possess a number of types of Class A receptors
with a few isoforms of each type. According to our ana-
lysis here, they express a few different isoforms of
adenosine, chemokine, dopamine, neuropeptide FF,
prostanoid and somatostatin receptors with a number of
other individual members from other types. Figure 3
shows that AtT20 cells have a limited breadth of Class
A orphan GPCRs. In Class B, AtT20 cells express
mRNA for a number of glucagon, orphan brain-specific
angiogenesis inhibitor (BAI), and orphan latrophilin
Figure 5 mRNA expression analysis of GPCR related signaling proteins. Microarray analysis of mRNA levels of GPCR related signaling
proteins for HEK293, AtT20, BV2 and N18 cell lines. The gray lines indicate the threshold of statistical significance and the dark bars are proteins
for which statistically significant levels of mRNA were detected. White bars indicate levels of mRNA for proteins that were present, but did not
reach statistical significance. Abbreviations: GRK = GPCR Kinase; PKA = Protein kinase A; PKC = Protein kinase C.
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Page 7 of 14receptors (figure 4A). Like HEK293 cells, AtT20 cells
express mRNA for GABABR1 (with a detectable, but not
significant level of GABABR2 mRNA), but unlike
HEK293s they express several metabotropic glutamate
receptor genes (figure 4B). For Class F/S in AtT20s we
detected mRNA for six frizzled receptors but not
smoothened receptor mRNA (figure 4C). AtT20’s have a
somewhat sparser repertoire of GPCR signaling-related
gene products than HEK293s, especially within the G
protein subunits (figures 5 and 6).
We next examined BV2 cells, a cell line that is often
used as a model system for the study of microglial func-
tion [32]. As shown in figures 1 and 2, BV2 cells predo-
minately possess mRNA for anaphylatoxin, chemokine,
and prostanoid Class A GPCRs as would be expected
from an immune system-derived cell line. They also
express mRNA for a scattering of other receptor types,
such as a few muscarinic, somatostatin, and lipid recep-
tors, among others. As has been reported in the litera-
ture, BV2 cells express CB2 cannabinoid receptors
(Cnr2) [33], which makes them unique among the other
cell lines examined here. We also observed the expres-
sion of a large number of different Class A orphan
G P C Rm R N A sa ss e e ni nf i g u r e3 ,t h o u g ham u c hl e s s
diverse repertoire of orphans from Class B (figure 4A)
or Class C (figure 4B) receptors were present. BV2 cells
express only one Class C GPCR at a significant, albeit,
low mRNA level: the metabotropic glutamate receptor,
mGluR1 (Grm1). Figure 4C shows that BV2 cells pos-
sess mRNA for a few different types of frizzled receptors
as well as the smoothened receptor. BV2 cells have a
wide complement of GPCR signaling-related gene pro-
ducts (figures 5 and 6). Though not quite as extensive
as HEK293 cells, BV2 cells possess numerous isoforms
of different phospholipases, PKA, PKC, and adenylyl
cyclase. Their beta-arrestin, RGS protein, and GRK
levels suggest the capacity to highly regulate GPCR sig-
naling as well.
Lastly we investigated the N18 cell line. This cell line
is derived from a neuroblastoma and is commonly
employed as a neuron-like cell line. It has been used as
a tool to analyze ion channel function in response to
toxins and other regulators [19,34-37]. We found that
N18 cells have mRNA for a broad range of different
C l a s sAG P C R sa ss e e ni nf i g u r e s1a n d2 .N 1 8c e l l s
have mRNA for a few types of muscarinic acetylcholine,
adenosine, chemokine, neuropeptides, prostanoids, pro-
tease-activated, and somatostatin receptors with a few
other individual types such as CB1 cannabinoid recep-
tors (Cnr1). Like the BV2 cells, N18 cells have mRNA
for quite a few Class A orphan GPCRs (figure 3) with a
similar profile as well. They further express mRNA for a
broad complement of Class B GPCRs (figure 4A) but
express a limited profile of Class C GPCRs (figure 4B).
They also have mRNA for a number of different types
of frizzled receptors, but lack mRNA for a smoothened
receptor (figure 4C). N18 cells express high levels of
many of the GPCR signaling-related gene products.
They have abundant levels of G proteins and numerous
isoforms of PKA. N18 cells’ GPCRs are also presumably
tightly regulated based on the assortment of GRK, RGS
and beta-arrestin mRNAs detected (figures 5 and 6).
In order to validate our findings with the microarray
analyses, we performed quantitative real-time PCR
(qPCR) analysis on these four cell lines. We chose a
range of GPCRs, mostly orphan receptors (Cnr1, Cnr2,
Gpr3, Gpr12, Gpr35, Gpr83, and Gpr119), as well as
two phospholipases (Plcb1 and Plcb4) as candidates to
measure their mRNA levels using this alternative
method. We selected genes that had distinct and dif-
ferential expression profiles across the four cell lines.
T h ed a t aa r ep l o t t e di nf i g u r e7i nam a n n e rt h a tc o r -
relates the copy number of mRNAs measured in each
cell line using qPCR with the levels of mRNA deter-
mined from our microarray experiments. The qPCR
data were broadly consistent with our microarray data.
We observed higher copy numbers for all genes for
which we had observed statistically significant microar-
ray expression, suggesting an overall good correlation
between our microarray and qPCR data. The qPCR did
detect mRNA for a few genes whose levels of expres-
sion did not reach statistical significance in the micro-
array analyses. These genes are Plcb4, Gpr3, and
Gpr92 in AtT20 cells and Plcb1, Gpr83 and Gpr92 in
N18 cells.
Discussion
The ability to induce expression of a known protein in a
model cellular system, such as the cell lines analyzed
here, has served as a remarkable, vital tool. However,
the GPCR research community that makes use of these
cell lines has had only limited data on the complement
of GPCRs and related signaling machinery expressed in
them. When a cell line is used for heterologous expres-
sion, ignorance of the endogenous protein expression
profile of a cell line may lead to false conclusions about
the nature of receptor function. Indeed, the cellular
milieu can have a dramatic impact on GPCR signaling
(see [22]. Microarray technology is now sufficiently
accessible and mature to determine the mRNA expres-
sion for cell lines from species whose genomes have
been sequenced. Yet even where microarray studies
have been conducted, their data remains only nominally
accessible to those with sufficient means, experience
and time to extract useful information. The absence of
a systematic published study of mRNA expression for
signaling proteins of general interest hinders research
using these important cell lines. This study provides
Atwood et al. BMC Genomics 2011, 12:14
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Page 8 of 14data examining the presence of several hundred differ-
ent GPCRs and related signaling proteins in four phe-
notypically diverse cell lines frequently used in GPCR
research.
H E K 2 9 3c e l l sa r ep e r h a p st h em o s tw i d e l yu s e dc e l l
line, cited in over four thousand publications and initial
work has identified a number of endogenous receptors
(see below). We expanded upon this knowledge by
demonstrating that HEK293 cells express at least 75 dif-
ferent GPCR mRNAs. Much of what has been reported
about GPCR mRNA expression patterns in HEK293
cells was confirmed by our analysis: ADORA2B,
CHRM3, F2R, F2RL1, GABABR1, GPCR5A, GPR19,
L G R 5 ,L P A R 1 ,L P A R 2 ,P 2 Y R 1 ,P T G E R 2 ,S 1 P R ,a n d
SSTR5 [17,26,38-46]. HEK293 cells have been reported
to possess mRNA for a number of receptors that were
not found to be expressed at statistically significant
levels in our study: 5HT1D, 5HT6, 5HT7, ADRA2(a-c),
ADRAB2, AGTR1, BDKRB2, DRD2, GPR1, GPR161,
GRM4, P2YR2 and SSTR2 [17,26,46-50]. Our results
also indicate that HEK293 cells express mRNA for most
G protein subunit isoforms, and numerous isoforms of
adenylyl cyclase, protein kinases A and C, and phospho-
lipase C. In addition they are useful for studying
Figure 6 mRNA expression analysis of GPCR related signaling proteins. Microarray analysis of mRNA levels of GPCR related signaling
proteins for HEK293, AtT20, BV2 and N18 cell lines. The gray lines indicate the threshold of statistical significance and the dark bars are proteins
for which statistically significant levels of mRNA were detected. White bars indicate levels of mRNA for proteins that were present, but did not
reach statistical significance. Abbreviations: ND = Not determined; PLA = Phospolipase A; PLC = Phospholipase C; PLD = Phospholipase D; RGS =
Regulator of G protein signaling.
Atwood et al. BMC Genomics 2011, 12:14
http://www.biomedcentral.com/1471-2164/12/14
Page 9 of 14regulation of G protein mediated signaling as significant
levels of mRNA for beta-arrestin1 and 2, GRK3-5 and a
number of RGS subtypes were seen.
Much less is known of the expression patterns of
G P C R si nA t T 2 0c e l l s .W ec o n f i r m e dt h ep r e s e n c eo f
Sstr1 and Sstr2 mRNA in AtT20 cells [30], but did not
observe significant levels of any of the other receptors
that have previously been reported such as Chrm4 [51],
Vipr1a, Adcyap1r1, or Sstr5 [30,52,53]. The lack of sig-
nificant levels of CRF receptor mRNA was of interest as
AtT20 cells have been reported to be sensitive to CRF
[54]. mRNA for Hrh3 or Hrh4 histamine receptors were
not detectable, despite reports of their presence [55,56],
but a low level of Hrh2 was found. Tacr1 [31] was not
detected, nor were Tacr2 and Tacr3. We also did not
detect the orphan Cmkor1/Cxcr7 [57]. It is worth not-
ing that there are at least two AtT20 clones available
and this may explain some of the differences we found.
Generally speaking, AtT20 cells possess a much less
diverse complement of GPCR-related signaling and reg-
ulatory gene products than the other cell lines tested.
Of the approximately 120 GPCR signaling gene products
that we studied here, AtT20 cells had 45 significantly
expressed signaling related proteins compared to 72 or
more in each of the 3 other cell lines. AtT20 cells were
the only ones to not have significant levels of beta-
arrestin1 (Arrb1) or GRK3-5. Only three RGS gene pro-
ducts were found at significantly high levels: Rgs14,
Rgs20, and Snx13.
BV2 cells are commonly used to study microglial biol-
ogy. These cells exist in a continuum between two
states: a resting state and an activated state. For exam-
ple, upon interferon gamma treatment (primed state),
BV2 cells increase both Cnr2 and Gpr55 mRNA levels,
whereas with lipopolysaccharide treatment (activated
state) these levels decrease [58]. In our case, BV2 cells
were cultured under conditions expected to promote a
resting state. We can confirm that as reported in the lit-
erature BV2 cells express Adora3 [59], Cnr2 [33,58],
Mtnr1a [60], Galr2 [61], Ccr5, Cxcr3 [62] and Rgs2, 10,
12 [27,28,63]. We also detected mRNA for receptors
that have been reported to be upregulated in response
to stimulation such as Ccrl2 [28,64], Ptafr, Ptigr [64]
and Rgs7 [65]. Here, too, we identified a few receptors
that have been reported present for which we found
levels of mRNA below the levels that we defined as sta-
tistically significant: Hcrtr1 [66], Gpr55 [58] and the
receptor for Cx3cr1 [67]. We did not detect Prokr1
which is upregulated with activation [27], nor for
Oprm1, P2ry1 and Gpr149 which are downregulated fol-
lowing activation [27,28]. Several reports have identified
t h ep r e s e n c eo fm G l u R si nB V 2a n dp r i m a r ym i c r o g l i a
[21,68,69]. Interestingly, Grm1 is generally thought not
to be present in BV2 cells, yet it was the only one that
we significantly detected. We did find low, non-signifi-
cant lev
els of Grm3, 6, and 8. The differences may be
due to differences in the activation state of the
cell lines. BV2 cells appear have a diverse
receptor and signaling gene product profile.
Of the cell lines tested, the least well characterized is
the N18 neuroblastoma line. They are known to express
Cnr1 [70], which we confirmed with our analysis. It has
been reported by some that they do not express mus-
carinic receptors [71], but our analysis shows that they
have mRNA for three different types (Chrm2, 3, and 4)
consistent with other reports [72,73]. These studies also
found evidence for secretin, prostacyclin, opioid and
alpha2-adrenergic receptors In support of this we found
significantly high levels of mRNA for Ptgir1, Ptger1,
Ptger3, Ptger4, Oprd1, Oprl1 and Adra2b. There were
also levels of mRNA for Sctr, Adra2a, Oprk1 and
Oprm1 that did not reach statistical significance.
Another report describes P2ry2 expression [74], but for
this we only found low non-significant levels. Beyond
these reports there seems to be little known of GPCR
signaling in this cell line and this analysis substantially
extends our knowledge of its complement of GPCR
expression, at least at the mRNA level. Like BV2 cells,
N18 cells appear to have a large repertoire of GPCRs,
effectors, and regulating proteins, being consistently one
of the highest expressers in each receptor class analyzed.
Interestingly, even the most prolific cell line expressed
only a small portion of the full repertoire of non-chemo-
sensory GPCRs (~360). Of these four cell types, BV2
Figure 7 Quantitative polymerase chain reaction validation of
microarray analysis. Quantitative PCR analysis of 10 genes from (A)
HEK293, (B) AtT20, (C) BV2, and (D) N18 cell lines. mRNA levels
determined from qPCR analysis were plotted against the mRNA
levels measured in the microarray analyses in figures 1, 3 and 6. The
dashed lines indicate the threshold of statistical significance for the
microarray data. Points that fall between 0 and this threshold
indicate genes that were detected with the microarray analysis but
failed to meet statistical significance. Lower critical threshold (Ct)
values indicate high mRNA copy numbers.
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Page 10 of 14cells expressed the highest total number of GPCRs (108)
followed by N18 (105), AtT20 (79), and HEK293 cells
(73). BV2 cells had the greatest total abundance of Class
A receptors (88), but had equal numbers of Class A
orphan GPCRs as N18 cells (figure 3). On the other
hand, HEK293 cells have mRNA for the greater number
of Class B and Class C orphans (figure 4). It is interest-
ing that the BV2 and the N18 cell lines, which are more
often used as models for specific cell types, express
mRNA for the most diverse set of receptors. This pre-
sumably results in a greater sensitivity to a broad spec-
trum of ligands and the large number of signaling
proteins for which we measured high mRNA levels in
these two cell lines attest to this. It is also of interest
that HEK293 and AtT20 cells have the lowest numbers
of GPCRs of these four lines. Low expression (both of
amount and type) may allow these cell lines to serve as
a better-differentiated cellm o d e l ,a n d ,f r o ma ne x p e r i -
mental perspective, may make a given cell line more
attractive as a ‘clean slate’ into which gene products of
interest can be introduced.
mRNA expression levels do not guarantee that a spe-
cific mRNA is properly translated, folded, and trafficked
to produce functional protein. Discrepancies between
our findings and those that have been reported using
P C R - b a s e dm e t h o d sm a yb ed u et od i f f e r e n c e st h a t
appear in cell lines with time, passage number and
growth conditions. Discrepancies may also be attributed
to the PCR-based techniques generally employed to
extract and amplify mRNA: in some cases the techni-
ques used in many of the studies cited here, some of
which do not allow for relative quantification, may have
detected very low levels of receptor mRNA that did not
reach our threshold for statistical significance. In light
of the potential discrepancies between microarray and
PCR-based techniques, we employed qPCR analysis to
test the validity of our microarray results (figure 7). The
overall consistency between our qPCR results and
microarray data lend confidence to the concept that the
microarray analyses accurately reflect the presence of
mRNA for these GPCRs and their signaling proteins.
Conclusions
In conclusion, this microarray analysis of the nearly full
complement of non-chemosensory GPCRs and related
signaling proteins in these four cell lines greatly expands
our understanding of their potential signaling repertoire.
These cell lines are used frequently as models of specific
cell types, in heterologous expression, and as controls
for antibody screening. The present work provides
accessible profiles of mRNAe x p r e s s i o nt h a tw eh o p e
will assist investigators of the GPCR superfamily in
choosing the appropriate cell line to study a particular
GPCR or related protein of interest and further to better
understand potential functional interactions between
GPCRs and related proteins in these lines. It is our hope
that this work can eventually be extended to other com-
monly used cell lines such as CHO and COS7 cells
when their host genomes (in this case hamster and
green monkey, respectively) have been sequenced and
made available for gene microarray analysis.
Methods
Cell cultures
Human Embryonic Kidney (HEK) (catalog #CRL-1573)
and AtT20 (catalog #CRL-1795) cells were purchased
from American Type Culture Collection (Boston, MA).
BV2 microglia cells were obtained from Dr. Nephi Stella
(University of Washington) [32,33]. N18 neuroblastoma
cells were obtained from Dr. William Catterall (Univer-
sity of Washington) [75]. Dulbecco’s modified Eagle’s
medium (DMEM), penicillin, streptomycin, and fetal
bovine serum (FBS) were purchased from Gibco Life
Technologies (Rockville, MD). All cell lines were grown
in DMEM with 10% FBS, 100 units ml-1 penicillin, and
100 μg ml-1 streptomycin at 37°C in 5% CO2 humidified
air. Importantly, BV2 cells were maintained in condi-
tions that push BV2 cells towards a resting, non-acti-
vated state.
Cell preparation, mRNA extraction & microarray analysis
Hybridization and sample imaging/quantification was
performed by Indiana University’s Center for Genomics
and Bioinformatics. To study mouse and human mRNA
expression, we used Nimblegen 4 × 72 k arrays (NCBI
MM8, and NCBI HG18, respectively; 60 mer probe
lengths). These are four-plex arrays that allow for the
examination of mRNA expression of ~20,000 genes
from four samples. The layout provides for three probes
per target, the values of which we averaged to obtain a
sample value. We cultured four 10 cm plates of each
cell line, performing separate extractions when the cells
grew to confluence. Total RNA was extracted from cells
using TRIzol reagent (Invitrogen) under RNase-free con-
ditions, followed by chloroform treatment (100 ul/ml).
After centrifugation, the aqueous phase containing total
RNA is then extracted and treated with isopropanol
(500 uL/mL) for 5-10 mins. After centrifugation, the
RNA pellet was isolated, washed with ethanol (75%; 1
ml/1 mL of reagent solution), followed by another cen-
trifugation and air-dried. The RNA pellet was resus-
pended in RNase-free water. Total RNA quantity was
assessed using NanoDrop ND-1000, and the Bioanalyzer
2100 determined the 28S/18S ratio for quality assessment.
To synthesize targets for hybridization, we began with
10.0 μg of total RNA and used Invitrogen’sS u p e r S c r i p t
Double-Stranded cDNA Synthesis kit using oligo (dT)
primer (Promega) followed by DNA labeling using 1 O.D.
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technologies) and 100 U Klenow fragment 3’ >5 ’ exo-
(NEB) per 1.0 μg double-stranded cDNA. Single-color
hybridization, post-hybridization washing and scanning
were done with NimbleGen reagents and according to
the NimbleGen’sU s e r ’s Guide for Expression Analysis.
Images were acquired using a GenePix 4200A scanner
with GenePix 6.0 software. The data from these arrays
were extracted using the software NimbleScan 2.4 (Roche
NimbleGen) and processed into PAIR files.
We used two separate NimbleGen high-density arrays
for expression analysis (design name = HG18 60 mer
expr 4plex and design name = MM8 60 mer expr X4).
The 4-plex arrays each consisted of 4 × 72,000 isother-
mal long-oligo nucleotide probes that are 60 nucleotides
in length. The first was based on HG18, Build 36 ver-
sion from NCBI of Homo sapiens gene catalog, which
represented 24,000 protein-encoding genes with 3
probes per target and 1 replicate, and the second was
MM8 version from NCBI of Mus musculus gene catalog,
which represented 18,869 protein-encoding genes with 3
probes per target and 1 replicate.
Quantitative polymerase chain reaction analysis
Primers for selected GPCRs and enzymes were designed
using Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/
primer-blast). The mouse gene was used as template in
the primer design, and either mouse or human genome
was used to screen for non-specific targets. Suitable pri-
mers were determined in this way and were commercially
produced (Integrated DNA Technologies, Coralville,
Iowa). AtT20, BV-2, HEK293 and N18 cell lines were
grown on 10 cm dishes until each monolayer was 50-95%
confluent. Total RNA was prepared and reverse tran-
scribed using a Retroscript Kit as per manufacturer’sp r o -
tocol (Cat# AM1710; Ambion Inc. Austin, Texas). Two
micrograms of total RNA from each line was reverse
transcribed, samples were diluted and qPCR was per-
formed using a Stratagene Mx3000P thermocycler and
Sybr Green/Low Rox polymerase mix (Cat.# 95056-100,
Quanta Biosciences, Gaithersburg, MD). In the case of
N18, the “no RT” control showed significant genomic
DNA contamination. To compensate for this, the total
RNA for this sample was treated with DNase 1 for 1
hour and again purified just prior to RT. Primers for glu-
taraldehyde-3-phosphate dehydrogenase (GADPH) were
used to make an internal control for each cell line with
the threshold cycle set at 16. Once the standard critical
threshold (Ct) was set, the relative expression levels for
genes within each cell line were determined.
Database information
All data is MIAME compliant and has been deposited in
GEO (accession number GSE25901).
Statistical analysis
For statistical analysis of the microarray data, we first
transformed the values from the microarray into log2
format for ease of comparison and data representation
[76]. We then obtained values for 10-11 assorted semi-
n a lp r o t e i n st h a tw e r eu n l i k e l yt ob ee x p r e s s e di nt h e s e
cell lines. For the human-derived HEK293 cells these
w e r e :P Y Y 2 ,P S P 9 4 ,S P A T A 3 ,S P A T A 4 ,S P A T A 5 ,
SPATA13, SPATS1, SPESP1, SPERT, ODF1, and
SPAM1. For the three murine cell lines we selected:
Svs2, Svs3, Svs5, Svs6, Svs7, Sva, Svp2, Sval1, Sval2,
Sval3. We averaged the expression level of each of these
proteins for each of the four plates to determine the
mean and standard deviation of their expression. We
took these mean values to represent zero expression. To
determine statistically significant expression, we added
the mean plus two standard deviations of the expression
levels of these seminal proteins for each plate. We then
subtracted this value from the value for each receptor
and protein for which we obtained a signal. The mean
plus two standard deviations was considered to be the
baseline for our proteins of interest as any values at this
level or higher would be considered statistically signifi-
cant (95% confidence that the true mean of the seminal
protein expression would fall within the mean plus two
standard deviations). Thus any protein remaining with a
positive expression value is considered to be significantly
expressed [76]. All graphs and statistical analyses were
generated using GraphPad Prism 4.0 software (Hearne
Scientific Software, Chicago, IL).
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